MA52795A - Dérivé de carbamoylpyridone polycyclique - Google Patents

Dérivé de carbamoylpyridone polycyclique

Info

Publication number: MA52795A
Authority: MA; Morocco
Prior art keywords: polycyclic carbamoylpyridone; carbamoylpyridone derivative; derivative; polycyclic; carbamoylpyridone
Prior art date: 2018-05-31

Application number

MA052795A

Other languages

English (en)

Other versions

MA52795B1 (fr

Inventor

Yoshiyuki Taoda

Yuto UNOH

Original Assignee

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-30

Publication date

2021-04-14

2019-05-30 Application filed by Shionogi & Co filed Critical Shionogi & Co

2021-04-14 Publication of MA52795A publication Critical patent/MA52795A/fr

2024-09-30 Publication of MA52795B1 publication Critical patent/MA52795B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA52795A 2018-05-31 2019-05-30 Dérivés de carbamoylpyridone polycycliques pour le traitement du vih MA52795B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2018104156		2018-05-31
PCT/JP2019/021446 WO2019230858A1 (fr)	2018-05-31	2019-05-30	Dérivé de carbamoylpyridone polycyclique
EP19810498.6A EP3805220B1 (fr)	2018-05-31	2019-05-30	Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Publications (2)

Publication Number	Publication Date
MA52795A true MA52795A (fr)	2021-04-14
MA52795B1 MA52795B1 (fr)	2024-09-30

Family

ID=68698918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA52795A MA52795B1 (fr)	2018-05-31	2019-05-30	Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Country Status (36)

Country	Link
US (3)	US11649236B2 (fr)
EP (2)	EP4257137A3 (fr)
JP (2)	JP7328962B2 (fr)
KR (2)	KR20250002769A (fr)
CN (2)	CN112513042B (fr)
AR (1)	AR115455A1 (fr)
AU (2)	AU2019277548B2 (fr)
BR (1)	BR112020024077A2 (fr)
CA (1)	CA3102063A1 (fr)
CL (1)	CL2020003002A1 (fr)
CO (1)	CO2020014294A2 (fr)
CR (2)	CR20200644A (fr)
DK (1)	DK3805220T3 (fr)
DO (1)	DOP2020000221A (fr)
EA (1)	EA202092921A1 (fr)
ES (1)	ES2984245T3 (fr)
FI (1)	FI3805220T3 (fr)
HR (1)	HRP20241221T1 (fr)
HU (1)	HUE068170T2 (fr)
IL (2)	IL313474A (fr)
LT (1)	LT3805220T (fr)
MA (1)	MA52795B1 (fr)
MD (1)	MD3805220T2 (fr)
MX (2)	MX2020012176A (fr)
MY (1)	MY198568A (fr)
PE (2)	PE20251594A1 (fr)
PH (1)	PH12020552000A1 (fr)
PL (1)	PL3805220T3 (fr)
PT (1)	PT3805220T (fr)
RS (1)	RS65891B1 (fr)
SG (1)	SG11202011382PA (fr)
SI (1)	SI3805220T1 (fr)
SM (1)	SMT202400330T1 (fr)
UA (1)	UA129229C2 (fr)
WO (1)	WO2019230858A1 (fr)
ZA (1)	ZA202007567B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020197991A1 (fr)	2019-03-22	2020-10-01	Gilead Sciences, Inc.	Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique
US20230058677A1 (en) *	2019-11-28	2023-02-23	Shionogi & Co., Ltd.	Polycyclic pyridopyrazine derivative
JPWO2021107066A1 (fr) *	2019-11-28	2021-06-03
BR112022015771A2 (pt)	2020-02-24	2022-10-11	Gilead Sciences Inc	Compostos tetracíclicos para tratar a infecção por hiv
EP4155312A4 (fr) *	2020-05-21	2024-06-19	Cisen Pharmaceutical Co., Ltd.	Dérivés cycliques fusionnés et leur utilisation en pharmacie
AU2021315475A1 (en) *	2020-07-27	2023-03-02	Cocrystal Pharma, Inc.	Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
TW202222798A (zh)	2020-09-30	2022-06-16	美商基利科學股份有限公司	橋接三環胺甲醯基吡啶酮化合物及其用途
CA3202957A1 (fr)	2021-01-19	2022-07-28	Hang CHU	Composes de pyridotriazine substitues et leurs utilisations
WO2023006087A1 (fr) *	2021-07-30	2023-02-02	南京明德新药研发有限公司	Composé de pyridone macrocyclique et son application
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120379998A (zh) *	2022-09-20	2025-07-25	吉斯凯(苏州)制药有限公司	多环氮杂环酮类化合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1549315A4 (fr)	2002-09-11	2007-05-23	Merck & Co Inc	Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
AU2003292437A1 (en)	2002-12-27	2004-07-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7858788B2 (en)	2005-02-21	2010-12-28	Shionogi & Co., Ltd.	Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
PL3372281T3 (pl)	2005-04-28	2021-12-27	Viiv Healthcare Company	Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
BRPI0617842A2 (pt) *	2005-10-27	2011-08-09	Shionogi & Co	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
NZ601847A (en)	2010-02-26	2014-03-28	Japan Tobacco Inc	1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
JP5766690B2 (ja)	2010-04-12	2015-08-19	塩野義製薬株式会社	インテグラーゼ阻害活性を有するピリドン誘導体
RU2014113230A (ru)	2011-10-12	2015-11-20	Шионоги Энд Ко., Лтд.	Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
EP2931730B1 (fr)	2012-12-17	2019-08-07	Merck Sharp & Dohme Corp.	Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
SI3067358T1 (sl)	2012-12-21	2019-12-31	Gilead Sciences, Inc.	Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AR094311A1 (es)	2012-12-27	2015-07-22	Japan Tobacco Inc	Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
SI2997033T1 (en)	2013-05-17	2018-04-30	Merck Sharp & Dohme Corp.	FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
EP3008044B1 (fr)	2013-06-13	2018-11-21	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
AU2014286993B2 (en)	2013-07-12	2018-10-25	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (fr)	2013-07-12	2018-07-21
WO2015039348A1 (fr)	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
HK1221648A1 (zh)	2013-09-27	2017-06-09	Merck Sharp & Dohme Corp.	用作hiv整合酶抑制劑的取代喹嗪衍生物
WO2015089847A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
WO2015199167A1 (fr)	2014-06-25	2015-12-30	日本たばこ産業株式会社	PROCÉDÉ POUR PRÉPARER UN DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET INTERMÉDIAIRE
WO2016027879A1 (fr)	2014-08-22	2016-02-25	塩野義製薬株式会社	Dérivé de pyridone polycyclique possédant une activité inhibitrice d'intégrase
EP3229804B1 (fr)	2014-12-09	2020-05-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques spirocycliques utiles comme inhibiteurs du vih
WO2016090545A1 (fr)	2014-12-09	2016-06-16	Merck Sharp & Dohme Corp.	Composés hétérocycliques spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016154527A1 (fr)	2015-03-26	2016-09-29	Merck Sharp & Dohme Corp.	Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
CA2980362C (fr)	2015-04-02	2020-02-25	Gilead Sciences, Inc.	Composes carbamoylpyridones polycycliques et leur utilisation pharmaceutique
WO2016187788A1 (fr)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
US10624912B2 (en)	2015-11-17	2020-04-21	Merck Sharp & Dohme Corp.	Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
WO2017087257A1 (fr)	2015-11-17	2017-05-26	Merck Sharp & Dohme Corp.	Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
US10544155B2 (en)	2015-12-15	2020-01-28	Merck Sharp & Dohme Corp.	Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (fr)	2015-12-31	2017-07-06	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih
JOP20190130A1 (ar)	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
KR20190086017A (ko)	2016-12-02	2019-07-19	머크 샤프 앤드 돔 코포레이션	Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
WO2019160783A1 (fr)	2018-02-15	2019-08-22	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
JP2021522254A (ja)	2018-04-27	2021-08-30	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
SG11202011386QA (en)	2018-05-31	2020-12-30	Shionogi & Co	Polycyclic pyridone derivative
WO2019236396A1 (fr)	2018-06-05	2019-12-12	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
CN108957755B (zh)	2018-07-27	2021-04-30	京东方科技集团股份有限公司	一种显示组件及其控制方法、平视显示器及汽车
WO2020197991A1 (fr)	2019-03-22	2020-10-01	Gilead Sciences, Inc.	Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique

2019
- 2019-05-30 LT LTEPPCT/JP2019/021446T patent/LT3805220T/lt unknown
- 2019-05-30 SM SM20240330T patent/SMT202400330T1/it unknown
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 KR KR1020247040377A patent/KR20250002769A/ko active Pending
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/fr not_active Ceased
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 RS RS20240971A patent/RS65891B1/sr unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/fr active Pending
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
- 2019-05-30 DK DK19810498.6T patent/DK3805220T3/da active
- 2019-05-30 IL IL313474A patent/IL313474A/en unknown
- 2019-05-30 MY MYPI2020006045A patent/MY198568A/en unknown
- 2019-05-30 FI FIEP19810498.6T patent/FI3805220T3/fi active
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/fr active Pending
- 2019-05-30 PE PE2025000789A patent/PE20251594A1/es unknown
- 2019-05-30 HR HRP20241221TT patent/HRP20241221T1/hr unknown
- 2019-05-30 SI SI201930798T patent/SI3805220T1/sl unknown
- 2019-05-30 PL PL19810498.6T patent/PL3805220T3/pl unknown
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 ES ES19810498T patent/ES2984245T3/es active Active
- 2019-05-30 MD MDE20210334T patent/MD3805220T2/ro unknown
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 UA UAA202008303A patent/UA129229C2/uk unknown
- 2019-05-30 IL IL279051A patent/IL279051B2/en unknown
- 2019-05-30 EP EP19810498.6A patent/EP3805220B1/fr active Active
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt unknown
- 2019-05-30 MA MA52795A patent/MA52795B1/fr unknown
- 2019-05-30 PT PT198104986T patent/PT3805220T/pt unknown
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 KR KR1020207037580A patent/KR102741390B1/ko active Active
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 HU HUE19810498A patent/HUE068170T2/hu unknown
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
2023
- 2023-03-22 US US18/124,827 patent/US12139489B2/en active Active
- 2023-08-03 JP JP2023127333A patent/JP7679427B2/ja active Active
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783A1/en active Pending
- 2024-06-26 US US18/755,191 patent/US20240352015A1/en active Pending

Also Published As

Publication number	Publication date
CN112513042B (zh)	2023-09-29
AU2019277548B2 (en)	2023-12-14
HUE068170T2 (hu)	2024-12-28
JPWO2019230858A1 (ja)	2021-06-24
BR112020024077A2 (pt)	2021-02-09
EP3805220A4 (fr)	2022-01-05
MA52795B1 (fr)	2024-09-30
DOP2020000221A (es)	2021-03-15
RS65891B1 (sr)	2024-09-30
MX2023010377A (es)	2023-09-12
US11649236B2 (en)	2023-05-16
EP3805220B1 (fr)	2024-07-31
HRP20241221T1 (hr)	2024-12-06
PE20210477A1 (es)	2021-03-11
DK3805220T3 (da)	2024-08-26
CL2020003002A1 (es)	2021-04-16
EP4257137A2 (fr)	2023-10-11
KR20250002769A (ko)	2025-01-07
AR115455A1 (es)	2021-01-20
CN112513042A (zh)	2021-03-16
ZA202007567B (en)	2022-04-28
EP3805220A1 (fr)	2021-04-14
JP2023145723A (ja)	2023-10-11
PE20251594A1 (es)	2025-06-16
SG11202011382PA (en)	2020-12-30
KR102741390B1 (ko)	2024-12-10
CR20200644A (es)	2021-02-05
CO2020014294A2 (es)	2020-12-21
CA3102063A1 (fr)	2019-12-05
IL279051B2 (en)	2025-01-01
EA202092921A1 (ru)	2021-04-07
PT3805220T (pt)	2024-08-16
AU2019277548A1 (en)	2021-01-14
SMT202400330T1 (it)	2024-09-16
CN117327072A (zh)	2024-01-02
UA129229C2 (uk)	2025-02-19
US20210122751A1 (en)	2021-04-29
ES2984245T3 (es)	2024-10-29
IL313474A (en)	2024-08-01
PH12020552000A1 (en)	2021-09-27
AU2024200783A1 (en)	2024-02-29
WO2019230858A1 (fr)	2019-12-05
MX2020012176A (es)	2021-01-29
CR20230571A (es)	2024-01-22
US20230227454A1 (en)	2023-07-20
EP4257137A3 (fr)	2023-11-01
IL279051A (en)	2021-01-31
KR20210015922A (ko)	2021-02-10
MY198568A (en)	2023-09-05
US20240352015A1 (en)	2024-10-24
JP7679427B2 (ja)	2025-05-19
US12139489B2 (en)	2024-11-12
SI3805220T1 (sl)	2024-10-30
JP7328962B2 (ja)	2023-08-17
MD3805220T2 (ro)	2024-10-31
IL279051B1 (en)	2024-09-01
PL3805220T3 (pl)	2024-11-04
FI3805220T3 (fi)	2024-08-30
LT3805220T (lt)	2024-08-26

Publication	Publication Date	Title
EP3690038A4 (fr)	2021-05-19	Conjugué anticorps-dérivé de pyrrolobenzodiazépine
EP3805220A4 (fr)	2022-01-05	Dérivé de carbamoylpyridone polycyclique
DK3810587T3 (da)	2022-10-31	Substituerede alkoxypyridinylindolsulfonamider
MA52802A (fr)	2021-04-14	Dérivé de pyridone polycyclique
LT3830085T (lt)	2024-02-12	Deuterinti lanifibranoro dariniai
EP3781060A4 (fr)	2022-01-26	Cryosonde
EP3645897A4 (fr)	2021-02-17	Monture
DK3768669T3 (da)	2023-04-24	Piperazinazaspiroderivater
PT4039675T (pt)	2024-09-16	Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3784463A4 (fr)	2022-01-19	Fluorosulfones
EP3885347A4 (fr)	2022-11-16	Dérivé de dihydropyrrolopyrazole
EP3805381A4 (fr)	2022-04-20	Phytase mutée
DK3823970T3 (da)	2024-02-05	Yderligere substituerede triazoloquinoxalinderivater
DK3823971T3 (da)	2022-09-05	Substituerede triazol-quinoxalin-derivater
EP3721129A4 (fr)	2021-09-08	Cryosphère
EP3831810A4 (fr)	2022-04-20	Dérivé de benzène
PT3796975T (pt)	2023-11-15	Derivados de sulfonilaminobenzamida
EP3590944A4 (fr)	2020-12-09	Dérivé d'azétidine
DK3894410T3 (da)	2023-11-27	Substituerede xanthinderivater
EP3770162A4 (fr)	2021-12-01	Dérivé de dihydrochromène
EP3805997A4 (fr)	2022-04-20	Nanocomprimé lipidique
EP3741757A4 (fr)	2021-11-03	Dérivé de dihydro-indolizinone
PL3880011T3 (pl)	2024-11-04	Sposób
EP3782983A4 (fr)	2022-01-26	Dérivé d'isoindole
EP3773733A4 (fr)	2022-05-25	Métallo-liothyronine